Tecentriq/Avastin combo hits progression-free survival target
admin 11th December 2017 Uncategorised 0Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.
More: Tecentriq/Avastin combo hits progression-free survival target
Source: News